Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.
about
B cells in chronic graft-versus-host diseaseGraft-versus-host disease: why have we not made more progress?Current and emerging strategies for the prevention of graft-versus-host diseaseThe Biology of Chronic Graft-versus-Host Disease: A Task Force Report from the National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host DiseaseRituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphomaAdministration of anti-CD20 mAb is highly effective in preventing but ineffective in treating chronic graft-versus-host disease while preserving strong graft-versus-leukemia effectsCurrent issues in chronic graft-versus-host disease.Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?Low-dose antithymocyte globulin enhanced the efficacy of tacrolimus and mycophenolate for GVHD prophylaxis in recipients of unrelated SCT.Aberrant B-cell homeostasis in chronic GVHDA phase II study of a nonmyeloablative allogeneic stem cell transplant with peritransplant rituximab in patients with B cell lymphoid malignancies: favorably durable event-free survival in chemosensitive patients.Clinical impact of H-Y alloimmunityAdvances and challenges in immunotherapy for solid organ and hematopoietic stem cell transplantationAllogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans.A phase II study of bortezomib plus prednisone for initial therapy of chronic graft-versus-host disease.Targeting Syk-activated B cells in murine and human chronic graft-versus-host disease.Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.Approaches for the prevention of graft-versus-host disease following hematopoietic cell transplantationCirculating T follicular helper cells with increased function during chronic graft-versus-host diseaseRecent advances on cellular therapies and immune modulators for graft-versus-host disease.Therapeutic benefits targeting B-cells in chronic graft-versus-host disease.Potential of glycosylation research in graft versus host disease after allogeneic hematopoietic stem cell transplantation.Emerging drugs for graft-versus-host disease.Chronic graft-versus-host disease: biological insights from preclinical and clinical studies.Mechanistic approaches for the prevention and treatment of chronic GVHD.Novel targets in the treatment of chronic graft-versus-host disease.Long-term outcome of Epstein-Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT.A review of late complications of allogeneic hematopoietic stem cell transplantations.Preferential depletion of host over donor T cells through in vivo decay of active rabbit-anti-thymocyte globulin levels during reduced intensity conditioning.Ofatumumab in combination with glucocorticoids for primary therapy of chronic graft-versus-host disease: phase I trial results.In vitro effects of different 8-methoxypsoralen treatment protocols for extracorporeal photopheresis on mononuclear cellsProtective Effect of Rituximab in Chronic Graft-Versus-Host Disease Occurrence in Allogeneic Transplant patients with Epstein Barr Virus Viremia.Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma.New and emerging therapies for acute and chronic graft versus host disease.The Role of Janus Kinase Signaling in Graft-Versus-Host Disease and Graft Versus Leukemia.Chronic Graft-versus-Host Disease: A Long Road Ahead.B-cell targeting in chronic Graft-versus-Host disease.Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease.Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant.Monitoring the kinetics of B-cell recovery following rituximab may guide the management of steroid-refractory chronic GvHD.
P2860
Q26861706-A593E18A-A03A-42DC-BA40-7A644A436C0AQ27012940-3D197DAB-11DC-42B5-A8B8-E0D87FE1AB0DQ27016541-08190DB0-2A49-4DC2-9140-F0D5DED8F0A5Q28076264-B9BAB729-E11B-4372-9D79-386C2CBBCC19Q33792160-D2F3499B-D7F5-4C9A-ABC6-ABF7A022868CQ33905411-96286A72-E678-498E-9489-7E03DD0C5EC0Q33917187-7F1C45E5-410B-42B8-A9BC-A29031C51BE4Q34769213-EECDBDD9-A496-4007-B34F-20E26094BAD5Q34860077-F4FDCFB9-DBB9-4CFF-87F7-5BFD7ED03CEDQ35171251-B779684E-ED84-4F3E-AF3B-E79878C06345Q35218515-8D2D0E3B-502B-4038-8D31-9FF44D1234FAQ35235186-BE50D66F-362C-4552-B3B4-062E07F94DFEQ35586614-D7D23D93-DEA4-4D55-9A9C-B31DB914DEBFQ35607308-E9A3773C-54CF-476C-B590-97111F54317EQ35737769-9A1BCFBC-165C-4104-B080-AD5DCF4E08E0Q35784522-BDD62CC4-BE75-4E38-B0AE-2404115D0BF8Q36264895-8B1E393D-7653-4A75-AAA9-4952653079C0Q36891433-5D9BB4C4-8CF0-43F2-B460-9EC27CC2508AQ36920466-9CF02AE5-679B-4C6E-9784-F2953D1FF59AQ38246755-606E63B8-76F1-4C43-82F6-641A20E85183Q38392246-0E1C42ED-A088-4B0D-920B-5810DDCFFBEAQ38753771-D4324EBB-BD86-4029-B3AF-BC7D5BA59FF7Q38786084-160B90C9-6AE3-4849-8DC2-4C7ED4EF0135Q39002164-5C7DD8CF-9EDC-4898-A5E4-98D6AD353C72Q39002166-BB1E04CC-47A7-49C5-9713-C89A0D55EB90Q39023963-388C7A22-A0B7-4B71-8722-53BD182920DBQ40042286-551B356A-8EF6-495C-8F2D-49A8E69D9A67Q40115697-B8A74421-D9A4-4530-BB3F-F9E6EF3F7634Q41179451-2910A81F-434C-46B8-80D7-15D93A0F9C87Q41387926-3C1E0E08-BE57-41F4-B22D-000D272C9381Q42203241-F8ACBCFD-1636-4438-B178-53441232CC97Q45325606-B6AB0CB1-D366-4B68-91F3-5766B4F406AAQ48573554-C168EE5F-C076-4DD8-98B3-BA16178C78C4Q49238507-53F3AFEA-F977-46D4-B4DF-B34BDA77D82DQ49384876-DB78E8B1-B376-48BC-B07A-15F561A27D1EQ49900740-BC3A7142-343D-4C40-AFFF-BD9E43CDA5E4Q50044417-830E7E5A-986F-4216-80D2-50C9A568516FQ50143234-48E1F701-8BBC-455C-A263-40B14BE61616Q52880975-3554F85B-9F64-4F89-92D8-637E1693BAA0Q52897641-1A4B2A9C-3610-44D4-82A4-4C67B6164F2A
P2860
Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 16 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rituximab prophylaxis prevents ...... n: results of a phase 2 trial.
@en
Rituximab prophylaxis prevents ...... n: results of a phase 2 trial.
@nl
type
label
Rituximab prophylaxis prevents ...... n: results of a phase 2 trial.
@en
Rituximab prophylaxis prevents ...... n: results of a phase 2 trial.
@nl
prefLabel
Rituximab prophylaxis prevents ...... n: results of a phase 2 trial.
@en
Rituximab prophylaxis prevents ...... n: results of a phase 2 trial.
@nl
P2093
P2860
P1433
P1476
Rituximab prophylaxis prevents ...... n: results of a phase 2 trial.
@en
P2093
Bhavjot Bindra
Brett Glotzbecker
Corey Cutler
Edwin Alyea
Haesook T Kim
Jacalyn Rosenblatt
Jerome Ritz
John Koreth
Joseph H Antin
Phandee Watanaboonyongcharoen
P2860
P304
P356
10.1182/BLOOD-2013-04-495895
P407
P577
2013-07-16T00:00:00Z